Research statistics
Afamelanotide research: publications and trials
At a glance
Publications, all years
124
Since 1988
Publications in 2026 so far
11
Through November 15, 2026
Human clinical research
31.7%
39 of 123 classified
Registered clinical trials
23
ClinicalTrials.gov
Randomized controlled trials
6
Publications reporting an RCT in people
Systematic reviews and meta-analyses
1
Preclinical studies
34.1%
20 animal · 20 in vitro · 2 computational
Records that only mention it
178
Not counted above
Status in the library: FDA-approved. Groups: Melanocortin agonists. 1 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Afamelanotide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 1988 | 0 | 1 | 0 | 0 | 1 |
| 1990 | 0 | 1 | 0 | 0 | 1 |
| 1994 | 0 | 2 | 0 | 0 | 2 |
| 1995 | 0 | 1 | 0 | 0 | 1 |
| 1996 | 0 | 2 | 0 | 0 | 2 |
| 1997 | 1 | 1 | 0 | 0 | 2 |
| 1998 | 0 | 1 | 1 | 0 | 2 |
| 2000 | 1 | 2 | 0 | 0 | 3 |
| 2001 | 0 | 1 | 0 | 0 | 1 |
| 2003 | 0 | 1 | 0 | 0 | 1 |
| 2004 | 1 | 0 | 0 | 0 | 1 |
| 2005 | 1 | 3 | 0 | 0 | 4 |
| 2007 | 0 | 2 | 0 | 0 | 2 |
| 2009 | 1 | 1 | 1 | 2 | 5 |
| 2010 | 0 | 2 | 3 | 0 | 5 |
| 2011 | 2 | 0 | 0 | 0 | 2 |
| 2012 | 1 | 3 | 0 | 0 | 4 |
| 2013 | 2 | 2 | 1 | 0 | 5 |
| 2014 | 1 | 0 | 1 | 1 | 3 |
| 2015 | 3 | 0 | 0 | 4 | 7 |
| 2016 | 1 | 1 | 4 | 0 | 6 |
| 2017 | 0 | 0 | 4 | 0 | 4 |
| 2018 | 0 | 0 | 1 | 0 | 1 |
| 2019 | 0 | 3 | 2 | 1 | 6 |
| 2020 | 3 | 1 | 3 | 0 | 7 |
| 2021 | 3 | 3 | 3 | 0 | 9 |
| 2022 | 3 | 0 | 1 | 0 | 4 |
| 2023 | 5 | 2 | 1 | 0 | 8 |
| 2024 | 2 | 2 | 2 | 2 | 8 |
| 2025 | 4 | 0 | 1 | 1 | 6 |
| 2026 (to date) | 4 | 4 | 2 | 1 | 11 |
Study types
| Review | 30 |
|---|---|
| Animal study | 20 |
| In vitro study | 20 |
| Observational human study | 16 |
| Editorial, letter or other | 11 |
| Other clinical trial | 10 |
| Case report | 7 |
| Randomized controlled trial | 6 |
| Computational study | 2 |
| Systematic review | 1 |
| Not yet classified | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Dermatology | 82 |
|---|---|
| Metabolic health | 39 |
| Gastrointestinal | 35 |
| Oncology | 15 |
| Neurological and mental health | 12 |
| Immune system | 10 |
| Tissue repair | 9 |
| Obesity and weight management | 8 |
| Cardiovascular | 5 |
| Antimicrobial and infectious disease | 4 |
| Endocrinology | 4 |
| Cognitive health | 2 |
Registered clinical trials
5 of 18 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 18 · Unknown status: 4 · Active, not recruiting: 1
Phase not applicable: 1 · Phase 1: 3 · Phase 1 / Phase 2: 1 · Phase 2: 12 · Phase 3: 6
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: A systematic review.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · December 14, 2022 · Systematic review · cited 22 times · open access
PMID 36525819 · DOI 10.1016/j.biopha.2022.114132 · Reviews and meta-analyses
- Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians.
Journal of the American Academy of Dermatology · January 25, 2020 · Randomized controlled trial · cited 32 times
PMID 31987791 · DOI 10.1016/j.jaad.2020.01.035 · Human clinical research
- Afamelanotide for Erythropoietic Protoporphyria.
The New England journal of medicine · July 1, 2015 · Randomized controlled trial · cited 283 times · open access
PMID 26132941 · DOI 10.1056/nejmoa1411481 · Human clinical research
- Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.
JAMA dermatology · January 1, 2015 · Randomized controlled trial · cited 188 times · open access
PMID 25230094 · DOI 10.1001/jamadermatol.2014.1875 · Human clinical research
- Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles.
Peptides · November 15, 2005 · Randomized controlled trial · cited 35 times
PMID 16293341 · DOI 10.1016/j.peptides.2004.12.038 · Human clinical research
- Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.
Archives of dermatology · July 1, 2004 · Randomized controlled trial · cited 58 times
PMID 15262693 · DOI 10.1001/archderm.140.7.827 · Human clinical research
- Skin pigmentation and pharmacokinetics of melanotan-I in humans.
Biopharmaceutics & drug disposition · April 1, 1997 · Randomized controlled trial · cited 44 times
PMID 9113347 · DOI 10.1002/(sici)1099-081x(199704)18:3<259::aid-bdd20>3.0.co;2-x · Human clinical research
- Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · September 1, 2026 · Other clinical trial · cited 0 times · open access
PMID 42678656 · DOI 10.1007/s43630-026-00986-x · Human clinical research
- Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.
Photochemistry and photobiology · March 2, 2026 · Other clinical trial · cited 0 times · open access
PMID 41766687 · DOI 10.1111/php.70081 · Human clinical research
- A feasibility and safety study of afamelanotide in acute stroke patients - an open label, proof of concept, phase iia clinical trial.
BMC neurology · July 26, 2023 · Other clinical trial · cited 4 times · open access
PMID 37496004 · DOI 10.1186/s12883-023-03338-9 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Afamelanotide for Erythropoietic Protoporphyria.
The New England journal of medicine · July 1, 2015 · Randomized controlled trial · cited 283 times · open access
PMID 26132941 · DOI 10.1056/nejmoa1411481 · Human clinical research
- Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.
JAMA dermatology · January 1, 2015 · Randomized controlled trial · cited 188 times · open access
PMID 25230094 · DOI 10.1001/jamadermatol.2014.1875 · Human clinical research
- Molecular determinants of ligand binding to the human melanocortin-4 receptor.
Biochemistry · December 1, 2000 · In vitro study · cited 170 times
PMID 11101306 · DOI 10.1021/bi001684q · In vitro studies
- Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407.
Journal of pharmaceutical sciences · September 1, 1996 · Animal study · cited 160 times
PMID 8877878 · DOI 10.1021/js960097g · Animal studies
- An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria.
The New England journal of medicine · January 1, 2009 · Editorial, letter or other · cited 127 times · open access
PMID 19144952 · DOI 10.1056/nejmc0805682 · Commentary and other
Latest publications
- Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study.
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · September 1, 2026 · Other clinical trial · cited 0 times · open access
PMID 42678656 · DOI 10.1007/s43630-026-00986-x · Human clinical research
- NDP-MSH rescues LPS-induced neuroinflammation, synaptic deficits, and depressive-like behaviors in mice: involvement of MC1R-cAMP/PKA signaling.
Frontiers in pharmacology · August 5, 2026 · Animal study · cited 0 times · open access
PMID 42621255 · DOI 10.3389/fphar.2026.1895800 · Animal studies
- The Synthetic Melanocortin Agonist NDP-MSH Ameliorates THSD7A-Associated Membranous Nephropathy in an Active Immunization Mouse Model.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · July 1, 2026 · Animal study · cited 0 times · open access
PMID 42394403 · DOI 10.1096/fj.202600817r · Animal studies
- Heterochiral co-assembly of β-strands and hairpins affords stereocomplexed peptide hydrogels for drug delivery.
Journal of controlled release : official journal of the Controlled Release Society · April 16, 2026 · In vitro study · cited 3 times · open access
PMID 41999898 · DOI 10.1016/j.jconrel.2026.114932 · In vitro studies
- Biodegradable polyurethane nerve conduits functionalized with NDP-MSH-loaded self-assembling peptide hydrogels for peripheral nerve regeneration.
Journal of materials chemistry. B · March 11, 2026 · Animal study · cited 0 times
PMID 41758331 · DOI 10.1039/d5tb02626a · Animal studies
- Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · March 6, 2026 · Observational human study · cited 1 times · open access
PMID 41793078 · DOI 10.1111/ddg.15996 · Human clinical research
- Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study.
Photochemistry and photobiology · March 2, 2026 · Other clinical trial · cited 0 times · open access
PMID 41766687 · DOI 10.1111/php.70081 · Human clinical research
- New and currently investigated pharmacotherapies for the erythropoietic protoporphyrias: spotlight on dersimelagon and bitopertin.
Expert opinion on pharmacotherapy · March 1, 2026 · Review · cited 0 times · open access
PMID 41885813 · DOI 10.1080/14656566.2026.2651281 · Reviews and meta-analyses
- Congenital Erythropoietic Porphyria with Persistent Severe Biochemical Abnormalities and a Non-Mutilating Clinical Course: A Case Report.
Reports (MDPI) · February 16, 2026 · Case report · cited 0 times · open access
PMID 41718315 · DOI 10.3390/reports9010065 · Human clinical research
- Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.
Journal of pharmaceutical and biomedical analysis · January 14, 2026 · Editorial, letter or other · cited 0 times
PMID 41547183 · DOI 10.1016/j.jpba.2026.117362 · Commentary and other
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Afamelanotide; CUV1647; melanotan-1; Melanotan I; NDP-MSH; SCENESSE
((TITLE_ABS:"Afamelanotide" OR CHEM:"Afamelanotide") OR (TITLE_ABS:"CUV1647" OR CHEM:"CUV1647" OR TITLE_ABS:"CUV 1647" OR CHEM:"CUV 1647") OR (TITLE_ABS:"melanotan-1" OR CHEM:"melanotan-1" OR TITLE_ABS:"melanotan1" OR CHEM:"melanotan1") OR (TITLE_ABS:"Melanotan I" OR CHEM:"Melanotan I") OR (TITLE_ABS:"NDP-MSH" OR CHEM:"NDP-MSH") OR (TITLE_ABS:"SCENESSE" OR CHEM:"SCENESSE")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Afamelanotide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/afamelanotide